Vascular invasion is one of the clinicopathologic features that are associated with early recurrence of human hepatocellular carcinoma (HCC). In this study, we have employed high-density Affymetrix oligonucleotide GeneChips (Affymetrix, Santa Clara, CA) to compare the expression profiles of HCC with and without vascular invasion. Data mining of the gene expression database established revealed that leukocyte cell-derived chemotaxin-2 (LECT2) transcripts were downregulated in HCC patients with vascular invasion. Expression of LECT2 in human HCC biopsies was significantly reduced (Po0.0001, fold change ¼ À7.2) when compared with non-tumorous adjacent liver tissues. The reduction of LECT2 expression was significantly correlated with the early recurrent and poor prognosis of the patient (P ¼ 0.024). To validate the ability of LECT2 to repress the growth of HCC, an adenoviral vector encoding the secreted human LECT2 (AdLECT2) was introduced into the human HCC cell lines Hep3B and PLC/PRF/5, which do not express endogenous LECT2. Over-expression of LECT2 resulted in the significant inhibition of in vitro migration and invasion of the AdLECT2-transfected HCC cells. Additionally, over-expression of AdLECT2 in subcutaneous Hep3B tumor xenografts in athymic nude mice resulted in significant inhibition of tumor growth (Po0.05). In summary, our data not only demonstrated that LECT2 is a candidate prognostic marker of human HCC, but also that therapeutic strategies targeting LECT2 expression is a promising therapy for human HCC.
Introduction
Hepatocellular carcinoma (HCC) is the most common primary malignancy of liver and exhibits a broad spectrum of clinical behaviors, with considerable molecular heterogeneity in tumor development and progression. 1 HCC is a difficult disease to manage clinically, and surgical resection and liver transplantation provide the best options for cure in selected patients. 2, 3 However, the long-term clinical outcome for HCC following tumor resection and liver transplantation remains unsatisfactory because of the high tumor-recurrence rate. 4, 5 Although various clinicopathologic variables have been described as predictive of post-transplant recurrence, the exact molecular mechanism(s) underlying HCC recurrence are still poorly understood. Vascular invasion is one of the clinicopathologic features reported to be strongly associated with the duration of tumor recurrence and survival. [6] [7] [8] [9] [10] Data-mining studies of a gene expression database that we have established earlier for Hepatitis B virus þ HCC patients 9 revealed that the transcripts of the leukocyte cell-derived chemotaxin-2 (LECT2) gene were specifically downregulated in the subgroup of HCC patients presented with vascular invasion at diagnosis.
LECT2 is a multi-functional protein that involves in chemotaxis, cell proliferation, inflammation, immunomodulation and carcinogenesis. [11] [12] [13] [14] [15] [16] [17] It was originally identified as a novel neutrophil-chemotactic protein by Yamagoe et al. in 1996. 17 LECT2 is a 16-kDa protein that consists of 133 amino acids and three intra-molecular disulfide bonds. 18, 19 The human LECT2 gene consists of four exons and three introns. 19 It has been mapped to chromosome 5q31.1-q32, a cluster harboring several genes encoding immuno-regulatory cytokines. These include interleukin (IL)-3, IL-4, granulocyte macrophage-colony stimulating factor and IL-5. 19 Subsequently, LECT2 has been shown to be synthesized by human hepatocytes 20, 21 and most hepatocytes show diffuse immune-staining for LECT2 within the cytoplasm. 16, 20 LECT2 is involved in many pathologic conditions. Recently, LECT2 has been identified as one of the proteins associated with human systemic amyloidosis. 22, 23 LECT2 amyloid was discovered in a patient who had nephritic syndrome and slowly progressive renal failure over a number of years. 22 However, clinical and pathological features of earlier phases of this type of amyloidosis have yet to be determined. Kameoka et al. 11 reported a polymorphism of the human LECT2 gene in the Japanese population associated with a severe form of rheumatoid arthritis that leads to progressive joint destruction. Using the concanavalin A-induced hepatic injury model, Segawa et al. 15 reported that LECT2 expression in the mouse liver was inversely regulated by TNF-a and/or IFN-g. Saito et al.
14 observed severe liver injury in LECT2À/À knockout mice compared with wild-type mice, following treatment with concanavalin A and correlated with the significant increase of natural killer T cells in the liver of the LECT2À/À knockout mice. These authors concluded that the increase of hepatic natural killer T cells could result from the excessive expression of IL-4 and Fas ligand in these mice, suggesting that LECT2 might regulate the homeostasis of natural killer T cells in the liver.
14 Using immunohistochemistry, Uchida et al.
16
demonstrated the reduction in LECT2 expression with the progression of hepatocarcinogenesis and its expression was abrogated in malignant HCC cells. Despite these observations, the direct function of LECT2 in hepatocarcinogenesis has not been well studied and its role in vascular invasion of human HCC has not been reported. In this study, we showed that re-expression of LECT2 significantly reduced the migration and invasion of human HCC cells in vitro and significantly reduced their growth in vivo.
Materials and methods

Patients and tissue specimens
Human HCC tissues and some of the corresponding distal noncancerous liver tissues were obtained from patients who had undergone partial hepatectomy at the National Cancer Centre, Singapore, with informed consent and conducted in accordance with the policies of the Institutional Review Board. This study consisted of specimens from vascular invasive (N ¼ 29) and non-invasive (N ¼ 51) HCC. As a control, histologically normal liver tissues (NN) from colorectal patients with liver metastases (N ¼ 10) and distal histologically normal surrounding tissues (ST) of HCC patients (N ¼ 27) were included in the analyses. Immediately after surgical resection, tissues were snap-frozen and stored in liquid nitrogen. Frozen sections of all tumor samples studied were evaluated by qualified pathologists to ascertain that the tissues studied were either cancerous (480% cancerous tissues) or normal.
Gene expression analysis: differential gene expression analysis of human HCC samples with or without vascular invasion Experiments were carried out as described previously. 24, 25 In brief, 5 mg of total RNA was extracted from HCC specimens, reversibly transcribed and biotin labeled. 
Adenoviral vector expressing recombinant human LECT2
All adenovirus vectors used in this study were replication deficient (E1/E3 deleted) and based on the serotype-5 adenovirus genome. 26 The cDNA of human LECT2 or firefly luciferase were cloned into a transfer plasmid, with expression driven by an human cytomegalovirus immediate early gene region promoter/enhancer, and mRNA stability and polyadenylation directed by a rabbit b-globin intron/ polyadenylation signal. The expression cassettes were introduced into a bacterial plasmid-borne adenovirus genome, using a recombination in bacteria. 27, 28 The resulting adenovirus genomes (AdLECT2 and AdLuc) were linearized with SpeI enzyme, transfected into E1-complementing human embryonic kidney 293 cells and were maintained in Dulbecco's modified Eagle's medium (DMEM) (Invitrogen, Grand Island, NY) until a cytophathic effect was apparent 5-7d post-transfection. Cells were collected and subjected to four freeze/thaw cycles. The supernatant was stored at À80 1C as crude viral lysate. An inoculum was added to 293 cells and the cycle was repeated three times to amplify the virus. The resulting recombinant Ad vectors were propagated in 293 cells and purified using AdenoPACK (Sartorius Stedium Biotech, Epsom, UK). Vector stocks were frozen at À80 1C until use. Quantification of viruses was based on protein content, 29 using the conversion 1 mg of viral protein ¼ 3.4 Â 10 12 viral particles (vp). 30 Typical vector stock titers were 10 12 vp/ml with a 1:100 infectious plaque forming unit to vector particle ratio.
Cell culture and virus transduction
Human HCC cell lines Hep3B and PLC/PRF/5 were cultured in DMEM, supplemented with 10% heat-inactivated fetal bovine serum (HyClone Labs, Logan, UT) and non-essential amino acids (Invitrogen) at 37 1C in 5% CO 2 -humidified incubator. For transduction experiments, cells were incubated with virus at a multiplicity of infection of 100vp in serum-free medium for 2 h at 37 1C, after which the virus inoculum was removed and cells were further maintained in culture medium for 2 days.
Immunoblotting At 48 h post-viral transduction, cell lysates were harvested. Protein concentrations were determined by the Bradford method. Cell lysates were mixed with loading buffer, denatured for 5 min at 95 1C, fractionated on a continuous SDS-polyacrylamide gel and blotted onto nitrocellulose membrane (Invitrogen). The membrane was immunoblotted with anti-LECT2 (1:6000 dilution; Medical & Biological Labs, Nagoya, Japan), anti-FLAG (1:1000 dilution; Stratagene, Cedar Creek, TX) and antiAd5 (1:1000 dilution; Abcam, Cambridge, UK) for 1 h at room temperature after which the membrane was washed and incubated with horseradish peroxidase conjugated goat anti-mouse or horseradish peroxidase-goat anti-rabbit immunoglobulin (1:2500 dilution; Pierce, Rockford, IL). Protein expression was normalized using an antibody against actin (Neomarker, Fremont, CA). Detection of positive signal was achieved using SuperSignal West Pico Substrate (Pierce).
Reverse transcription-PCR All human tissue samples were obtained from the National Cancer Centre Singapore Tissue Repository. Hep3B and PLC/PRF/5 cells were transduced with AdLECT2 or AdLuc at a multiplicity of infection of 100vp for 48 h. All samples were lyzed and total RNA was extracted with RNeasy mini kit (Qiagen, Valencia, CA). Reverse transcription-PCR was performed using the SuperScript III First-Strand Synthesis System (Invitrogen) according to manufacturer's instruction, using primer pairs as described previously. 13 The products were separated by electrophoresis on 1.5% agarose gel and stained with ethidium bromide.
In vitro experiments on migration and invasion: scratch wound assay Adenoviral vectors transduced cells were seeded in 6-well plate and incubated until a monolayer of cells was formed. A scratch was made in the middle of the well with a sterile paper clip. The debris was washed away and conditioned media was added to the wells. Cells were imaged at Â 100 microscopy magnification, and the initial area of the scratch (area devoid of cells) for the field of view was measured with Image-Pro Plus software (Media Cybernetics, Acton, MA). The plate was incubated at 37 1C and the same field of view was imaged at 24, 48 and 72 h. The percentage of wound closure by migrating cells over time was derived from the final area of the scratch wound divided by the initial area.
In vitro experiments on migration and invasion: Boyden chamber assay The effect of LECT2 on the migration of HCC cells was evaluated using a transwell chamber with 8 mm pore size polycarbonate membranes (Becton Dickson, Bedford, MA). Cells were transduced with AdLECT2 at multiplicity of infection of 100vp, cultured for 48 h before seeding at a density of 2 Â 10 4 cells in 250 ml of 1% bovine serum albumin supplemented DMEM in the upper transwell chamber. In the lower chamber, 750 ml DMEM containing 10% fetal bovine serum was added. Cells were allowed to migrate across the polycarbonate membranes and analyzed at 72 h after cell seeding. A cotton swab was used to wipe off non-invading cells on the upper surface of the membrane. The invading cells on the lower surface of the membrane were fixed and stained with Hoescht 333548 (Molecular Probes, Eugene, OR). Using Â 200 magnification, cells invading the membranes were counted in three microscopic fields. For each group, three duplicate wells were studied. The invasion assay was done in a similar manner but with growth factor-reduced Matrigel coating on the polycarbonate membranes. . Equal volumes of saline were given to each of the three mice as controls for the effect of vp administration on tumor growth. Animals were killed at day 28 after injection of the first therapeutic dose. Tumor dimensions were measured using a digital caliper and the tumor volume (V) was calculated using the formula: V ¼ p/6 Â length Â (width) 2 . Growth curves were plotted using relative tumor volume for each experimental group at the set time points.
Tumor model
Statistical analysis
Analysis of variance (ANOVA) and the Student's t-test were used for comparison among groups and between matched data, respectively. We used GraphPad Prism 5.0 (GraphPad Software, San Diego, CA) for the statistical calculations. A P value of less than 0.05 was considered to be statistically significant.
Results
Expression of LECT2 in human HCC biopsy samples from patients with vascular invasion is significantly reduced Vascular invasion is an adverse prognostic factor in human HCC associated with early recurrence. Datamining studies of a gene expression database that we have established for Hepatitis B virus þ HCC patients revealed that expression of LECT2 was reduced in HCC biopsy samples (N ¼ 80) compared with adjacent histologically normal liver tissues (N ¼ 37). In Figure 1 , we showed that LECT2 expression in HCC without vascular invasion (NI, N ¼ 51) is significantly differed from matchednormal surrounding tissues (ST) (Po0.0001, fold change ¼ À2.35). In comparison, LECT2 expression in HCC with vascular invasion (VI, N ¼ 29) is even more significantly differed from ST (Po0.0001, fold change ¼ À7.29) (Figure 1a) . Expression of LECT2 between HCC with and without vascular invasion is also significantly differed with P ¼ 0.0006 and fold change ¼ À3.1 (Figure 1a) . To validate the results obtained from the microarray data on the downregulation of LECT2 in HCC biopsy samples with VI, the mRNA level of LECT2 in randomly selected VI-HCC biopsy samples (N ¼ 19) and NI-HCC biopsy samples (N ¼ 28) used in genome-wide gene expression analysis were determined by real-time PCR. Consistent with the results obtained from genome-wide gene expression analysis, expression of LECT2 was significantly reduced in VI-HCC samples compared with NI samples (Po0.05, fold change ¼ À3.98) (Figure 1b) . No significant difference was detected between normal liver tissues (NN) and the adjacent histologically normal tissues of HCC specimens (ST). Furthermore, using reverse transcription-PCR, it was determined that LECT2 was only expressed in fetal liver, adult liver and testis normal tissues (Figure 2) .
To elucidate the functional role of LECT2 in HCC, we correlated the level of expression of LECT2 with the various major clinicopathologic variables available at diagnosis. Univariate analysis showed that the downregulation of LECT2 was statistically significantly correlated with VI (P ¼ 0.001) and tumor recurrence (P ¼ 0.029) ( Table 1 ). Nearly 40% of HCC patients with their LECT2 expression downregulated recurred in less than 6 months post-resection compared with an observed recurrent rate of less than 20% for HCC patients with comparatively higher LECT2 expression (P ¼ 0.024, Figure 3 ). These data corroborated well with the suggestion that LECT2 has a significant role in vascular invasion, and the recurrence of human HCC and HCC cells with downregulated LECT2 expression could have enhanced invasion/metastasis potentials.
Construction of adenoviral vector carrying the LECT2 gene Adenoviral vector encoding secreted human LECT2 was constructed and was employed to deliver the LECT2 into the human HCC cell line Hep3B. LECT2 gene could be detected in AdLECT2-transduced cells but not in the parental or AdLuc-transduced control cells (Figure 4a ). This was further confirmed at the protein level using western blot. The presence of adenoviral vectors in the transduced cells was confirmed with anti-Ad5 antibody at 24 and 48 h post-infection (Figure 4b ), but at 96 h postinfection, viral fiber protein could no longer be detected, whereas LECT2 protein was still present (data not shown). This observation is likely due to the leaky expression of the early and late genes of the replication defective Ads immediately following infection.
Over-expression of LECT2 in Hep3B and PLC/PRF/5 human HCC cells suppressed the migration and invasion ability of these cells in vitro First, we employed the scratch wound-healing assay to evaluate the effect of LECT2 on the migration ability of HCC cells in vitro. As shown in Figure 5a , re-expression of LECT2 in Hep3B cells following adenoviral delivery significantly reduced the ability of these cells to migrate across a scratch wound. Semi-quantitative analysis also (Figure 5b ). Using Boyden chambers, the ability of LECT2 to inhibit the migration and invasion of HCC cells was also studied. Hep3B and PLC/PRF/5 cells were transduced with AdLECT2. Following transduction with AdLECT2, the migratory ability of Hep3B and PLC/PRF/5 cells through the polycarbonate membranes was significantly reduced (Po0.01 and Po0.001, respectively) (Figure 6a ). The number of cells invaded through the matrigel-coated membrane in the AdLECT2-transduced Hep3B cells was reduced by more than 80% when compared with AdLuctransduced control cells (216±7 versus 1151±187, Po0.01) (Figure 6b ). Similar trends of suppression of invasion could also be observed with PLC/PRF/5, following transduction with AdLECT2. However, the P-value obtained (P ¼ 0.052) was not statistically significant (Figure 6b ). These findings indicate that overexpression of LECT2 could have a significant inhibitory effect on the migration and invasion of human HCC cells.
Over-expression of LECT2 significantly reduced the tumorigenicity of HCC cells in vivo
The therapeutic effect of LECT2 in vivo was evaluated using a Hep3B subcutaneous xenograft model. Hep3B tumor-bearing mice were given AdLECT2 (N ¼ 13) or AdLuc (N ¼ 12) at a dose of 1 Â 10 10 vp in 100 ml saline by LECT2 inhibits growth of human HCC cells HT Ong et al direct evidence that LECT2 can be a potential therapeutic strategy for human HCC.
Discussion
Recurrent disease remains one of the major challenges for the management of HCC patients following resection or liver transplantation, accounting for 50-90% of postoperative death. 4, 8, 31 Vascular invasion is an adverse prognostic factor in human HCC associated with early recurrence. Tumor invasion and metastasis are complicated processes involving many different classes of proteins, such as cell-adhesion molecules, extracellular proteases, angiogenetic factors, cytokines and growth factors. In this study, we have shown that reduction in LECT2 is significantly associated with HCC vascular invasion.
A 16-kDa secreted protein, LECT2 was first isolated as a possible chemotactic factor for neutrophils. 17 This protein is synthesized by hepatocytes and has been associated with repair and cell growth after damage. 16, [32] [33] [34] Accumulating evidence suggests that LECT2 is a pleiotropic protein, as are many cytokines. LECT2 has an important role in neuronogenesis, and its mutation is the major cause of primary microencephaly. 35 Despite these observations, the significance of LECT2 in human cancer has not been fully investigated. Here, we showed that the majority of samples from HCC patients that had vascular invasion at diagnosis had downregulated LECT2 expression compared with most of the non-recurrent HCC samples that did not have vascular invasion at diagnosis. The expression of LECT2 was three-fold lower in HCC samples with vascular invasion at diagnosis compared with HCC with no vascular invasion, and approximately eight-fold reduced compared with histologically normal adjacent tissues (Figure 1 ). Uchida et al. 16 had reported that the expression of LECT2 was almost abrogated in full-blown HCC cells compared with lowgrade malignant HCC (LGM-HCC) and pre-malignant atypical hyperplasia (AH). The decreased expression of LECT2 in HCC is also in accordance with other reports. 13, 36 To analyze the relationship of the expression level of the LECT2 gene with the clinicopathologic features of HCC patients made available at diagnosis, univariate analysis was performed and demonstrated that only vascular invasion and recurrent status statistically significantly correlated with the expression of LECT2. This was further supported by the significant difference in recurrence observed in HCC patients with high and low LECT2 expression. To examine the function of LECT2 in HCC, we over-expressed LECT2 in the human HCC cell lines. LECT2 significantly suppressed the migration and invasion of the transfected cells in vitro. In addition, we also found that intra-tumoral injection of AdLECT2 into nude mice bearing subcutaneous Hep3B xenografts resulted in significant inhibition of tumor progression.
To date, little is known of the molecular role of LECT2 in liver carcinogenesis. Using a Wnt-responsive TOPflash reporter system, Phesse et al. 37 demonstrated that LECT2
is an inhibitor of the Wnt signaling pathway. The Wnt signaling pathway has been shown to have critical roles in cell development, proliferation and differentiation. 38, 39 Therefore, alterations of this pathway within cells and between cells could disrupt the balance between cell-tocell interactions. 40, 41 Loss of this delicate cell-to-cell contact resulting from the reduction of LECT2 during hepatocarcinogenesis could lead to the increase migration observed in tumor cells, resulting in tumor invasion and metastasis. 40, 41 This hypothesis supports our observation that reduced expression of LECT2 in HCC cells enhanced their migration and invasion properties. In accordance, increased LECT2 expression in HCC cells following Ad-mediated LECT2 gene expression inhibit tumor growth in vivo and tumor migration and invasion in vitro. Hence, besides being a candidate-prognostic marker of human HCC, the loss of LECT2 expression in human HCC is of functional importance and relevant to the development and progression of the disease. Therefore, LECT2 could potentially be a key player in the development of HCC, and manipulating the expression of LECT2 in HCC cells is a promising therapeutic strategy for human HCC therapy.
